Capricor Therapeutics Announces Late-Breaking Presentations At 28th Annual Congress Of tThe World Muscle Society
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics (NASDAQ:CAPR) presented data at the 28th Annual Congress of the World Muscle Society, showing the sustained efficacy and safety of CAP-1002 in treating Duchenne Muscular Dystrophy. The data also highlighted the potential of the company's StealthX™ technology in enhancing the delivery of antisense oligonucleotides. The company plans to report the outcome of the interim futility analysis in Q4 2023 and top-line data in late 2024.
October 10, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics' presentations at the World Muscle Society Congress highlight the potential of its CAP-1002 and StealthX™ technology, which could positively impact the company's stock in the short term.
The positive data presented by Capricor Therapeutics on its CAP-1002 and StealthX™ technology could increase investor confidence in the company's potential, leading to a possible increase in its stock price. The upcoming interim analysis in Q4 2023 and top-line data in late 2024 could further influence the stock's performance.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100